REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

Wed, 13th Apr 2022 11:06

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 59% at 9.00 pence, 12-month range 4.80p-10.90p. "Delighted" with positive data from the Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, as part of the new optimised international Phase 3 trial of Lupuzor in lupus patients. Study shows PK study has met the key endpoints requested by the FDA. "This positive PK data now clears the path for commencement of all clinical studies within the P140 platform. In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy," company notes.

----------

Shearwater Group PLC, up 25% at 136.42 pence, 12-month range 70.00p-230.00p. Subsidiary Brookcourt Solutions wins "significant" new contract win to the potential value of up to about GBP21.0 million with unnamed "leading telecommunications and media company". Initial, secured value of the contract, across an initial three year term, is GBP12.9 million, with the contract including an option to extend by a further two years for a total additional value of about GBP8.0 million.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 13% at 1.50 pence, 12-month range 1.00p-3.90p. Notes no individual or entity tied to company's AO Kun-Manie mine have been sanctioned in any round of EU, UK and US sanctions against Russia. Mine is in far east of Russia. Also notes flow of funds supporting AO Kun-Manie continue and company has now ensured sufficient cash reserves for the subsidiary covering budgeted costs through the first half 2022. Previously, AO Kun-Manie funds have been delivered to cover a 30 to 45 day period. Does say, however, company's lead legal consul representation in Moscow, Bryan Cave Leighton Paisner, is suspending operations within Russia. Company is reviewing options for lead Russian legal representation.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Nov 2015 10:44

ImmuPharma's Lupuzor trial on track for 2017 completion

(ShareCast News) - ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor. The AIM listed company provided an update to the market on Wednesday about the drug trial, its lead programme for the potential breakthrough compound for life threatening auto imm

Read more
4 Nov 2015 10:31

WINNERS & LOSERS SUMMARY: Housebuilders And Estate Agents Torn Down

Read more
4 Nov 2015 08:56

ImmuPharma Says Lupuzor Trials Set To Start In US This Year

Read more
30 Sep 2015 09:29

ImmuPharma Appoints Non-Executive Chairman As Loss Narrows

Read more
29 Jul 2015 09:16

ImmuPharma Says Chairman And Co-Founder Richard Warr Dies

Read more
27 Jul 2015 07:08

ImmuPharma Secures Financing To Continue Lupuzor Progress (ALLISS)

Read more
29 May 2015 07:28

LONDON MORNING BRIEFING: AB Foods Lifted To Buy From Sell By Goldman

Read more
29 May 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
28 May 2015 16:28

AGM, EGM Calendar - Week Ahead

Read more
6 May 2015 08:11

ImmuPharma Chairman Takes Leave To Deal With Health Issue

Read more
30 Apr 2015 09:37

Immupharma To Focus On Lupuzor, 2014 Loss Narrows On Trial End

Read more
11 Feb 2015 12:18

Immupharma Says Cancer Therapy Trial Meets Primary Objective

Read more
22 Jan 2015 12:00

UK MIDDAY BRIEFING: Royal Mail Up As It Meets Low Expectations

Read more
22 Jan 2015 11:19

UK WINNERS & LOSERS: Oxford Instruments Falls On Another Warning

Read more
22 Jan 2015 08:32

ImmuPharma Shares Up 22% On Simbec-Orion Lupuzor Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.